Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medicis, a specialty pharmaceutical company, has received notice of allowance from the US Patent and Trademark Office for the company's US patent application directed to the use of Solodyn in 90mg tablet form.
Subscribe to our email newsletter
The newly allowed claims include subject matter covering methods of using a controlled-release oral dosage form of minocycline to treat acne.
Solodyn has one issued US patent, which expires in 2018, related to the use of the Solodyn unique dissolution rate. Solodyn is available by prescription in 45mg, 90mg and 135mg extended release tablet dosages.
Jonah Shacknai, chairman and CEO of Medicis, said: “We are pleased to announce receipt of this notice of allowance by the US Patent and Trademark Office. This represents an important element of maintaining the Solodyn franchise. These allowed patent claims, when issued, will enhance the intellectual property protection of our Solodyn brand.”